Profound Medical Corp. (PRN:CA) Q3 2025 Earnings Call Transcript
Access earnings results, analyst expectations, report, slides, earnings call, and transcript.
Overview
The earnings call reveals strong financial performance with an 87% revenue increase and improved gross margins. Positive guidance with 70%-75% growth expectations, supported by a robust pipeline, indicates optimism. The Q&A highlights significant commercial payer rates and Medicare reimbursement progress, enhancing profitability potential. While there are competitive and operational risks, the company's strategic focus on reimbursement and market access, along with promising clinical outcomes, supports a positive outlook. Despite some management vagueness, the overall sentiment is positive, likely resulting in a 2%-8% stock price increase.
Key Financial Performance
Revenue $5.3 million in Q3 2025, up 87% from $2.8 million in Q3 2024. This increase was driven by $4.1 million from recurring revenue and $1.2 million from one-time sales of capital equipment.
Gross Margin 74.3% in Q3 2025, compared to 63.1% in Q3 2024. The improvement reflects growing efficiency and scale of commercial operations.
Operating Expenses $12.8 million in Q3 2025, up from $10.8 million in Q3 2024. The increase is attributed to R&D and SG&A expenses.
Net Loss $8 million or $0.26 per share in Q3 2025, down from $9.4 million or $0.38 per share in Q3 2024. The reduction in net loss is due to increased revenue and improved gross margins.
Cash Position $24.8 million as of September 30, 2025. The company expects cash burn to decline as revenue grows and margins remain high.
You have reached the limit. Sign up to access full content
Get started
Operating Highlights
TULSA-AI Volume Reduction software: Full product release to be launched at RSNA 2025. Designed to shrink benign and large prostates caused by BPH. Offers AI-powered planning and accelerated ablation with efficient workflows. Early surgeon feedback has been positive, with increased utilization expected in 2026.
Sonalleve: Technology for treating uterine fibroids, adenomyosis, and potentially pancreatic cancer. Currently operational in Europe, China, and Southeast Asia. Over 4,000 women treated for uterine conditions. Potential for expansion in Gulf countries and Brazil.
TULSA-PRO adoption: Broader adoption across academic and community hospitals. 70 TULSA-PRO sites operational, with 93 new systems in the sales pipeline. Strategic partnerships established in Saudi Arabia, Australia, New Zealand, and with Siemens.
Sonalleve market expansion: Interest from Gulf region countries and Brazil for interventional MRI and Sonalleve technology.
Revenue growth: Q3 2025 revenue increased by 87% year-over-year to $5.3 million. Gross margin improved to 74% from 63% in Q3 2024.
Cost management: Net loss reduced to $8 million in Q3 2025 from $9.4 million in Q3 2024. Cash burn expected to decline as revenue grows.
Profitability strategy: Focus on achieving 200 TULSA-PRO sites with 50 procedures per site annually. Targeting $85 million annual revenue with high margins to achieve profitability.
AI-powered software upgrade: Upgrading software to include simpler workflows for BPH patients, enabling efficient scheduling and treatment days.
You have reached the limit. Sign up to access full content
Get started
Risk or Challenges
Financial Performance: The company recorded a net loss of $8 million in Q3 2025, though it was an improvement from the $9.4 million loss in Q3 2024. Operating expenses increased to $12.8 million from $10.8 million in the same period last year, which could strain financial resources if revenue growth does not keep pace.
Future Financing Uncertainty: The company has no immediate plans for financing but intends to file an S-3 registration to keep options open. This could lead to shareholder dilution if financing becomes necessary.
Regulatory and Reimbursement Challenges: While some commercial payers are covering procedures on a case-by-case basis, there are still instances of initial denials and appeals. This mixed reimbursement landscape could hinder broader adoption of the technology.
Market Adoption Risks: Although the TULSA-PRO platform is gaining traction, broader adoption depends on achieving compatibility with new Siemens Interventional MR systems and securing national or regional coverage decisions from commercial payers.
Competitive Pressures: The company faces competition from other prostate treatment technologies like HIFU, IRE, and cryotherapy. While TULSA-PRO offers unique features, convincing clinicians to adopt it over existing methods remains a challenge.
Supply Chain and Distribution Risks: The company relies on strategic partnerships and distribution agreements in various regions. Any disruptions in these partnerships could impact market penetration and revenue growth.
Economic and Operational Risks: The company’s profitability depends on scaling operations and achieving high utilization rates at TULSA-PRO sites. Economic downturns or operational inefficiencies could delay profitability.
You have reached the limit. Sign up to access full content
Get started
Guidance & Outlook
Revenue Growth: The company expects to achieve high double-digit growth with high margins, aiming for profitability and continued profitable growth.
Cash Flow: Profound Medical anticipates a decline in cash burn and eventual transition to cash flow positive as revenue grows and margins remain high.
TULSA-AI Volume Reduction Software: The full product release will be launched at the RSNA annual meeting, with expectations to increase utilization in BPH procedures to double-digit percentages of total procedures in 2026.
TULSA-PRO Expansion: The company aims to achieve an installed base of 200 TULSA-PRO sites, with 50 procedures per site per year, generating $55 million in procedure revenue, $10 million in annual service revenue, and $20 million in new capital revenue.
Reimbursement and Coverage: Profound Medical expects to secure national or regional coverage decisions from commercial payers starting mid-2026, supported by clinical data.
Sonalleve Technology: The company plans to expand the use of Sonalleve for treating uterine fibroids, adenomyosis, and potentially pancreatic cancer, with increasing interest from international markets.
You have reached the limit. Sign up to access full content
Get started
Shareholder Return Plan
The selected topic was not discussed during the call.
You have reached the limit. Sign up to access full content
Get started
Key Q&A
Q:Could you provide more color on the utilization improvement in Q3 and its continuation into Q4?
A:The improvement in utilization is driven by the CPT1 coding and Medicare reimbursement, which is progressing as expected. Additionally, the market access and patient access teams are working on obtaining private insurance coverage. Tailwinds include Medicare patients moving away from a cash-pay-only market, individual wins with private insurers, and growing global interest in the technology. Patients are also seeking TULSA-PRO based on their own research and results.
Q:Are commercial payer rates roughly double Medicare rates?
A:Yes, commercial payer rates are significantly higher than Medicare rates. For example, Medicare payments are around $13,000 per patient, while commercial payments range from $25,000 to $65,000 per patient. Contribution margins are $3,000 to $4,000 per patient for Medicare and significantly higher for commercial payers.
Q:How many of the 93 sites in the engage stage are expected to become customers, and over what time period?
A:The 93 sites are in the Verify, Negotiate, and Contracting phases, which are the tail end of the pipeline. Management expects a significant portion to close by Q4 2025, with the pipeline providing confidence for growth into 2026.
Q:Does the 70%-75% growth guidance for the year still stand?
A:Yes, management remains comfortable with the 70% growth target, supported by the addition of 3 new sites in Q4 and a strong pipeline.
Q:What is driving the gross margin improvement, and what is the long-term target?
A:Gross margins have improved to over 74%, driven by both recurring revenue and capital sales. Management expects margins to stabilize in the low 70% range.
Q:What is the fallout rate in the negotiation and contracting stages of the pipeline?
A:Management estimates a 50% closing rate for the current pipeline, which could increase to 65% as the sales team gains more experience.
Q:Is the 70 total installed units as of Q3 or current?
A:The 70 installed units include 3 deals closed in Q4, so the number reflects the current total.
Q:What upcoming data reveals are expected to have the highest impact?
A:Upcoming data on BPH treatment efficacy and comorbidities, as well as reimbursement data, are expected to drive adoption and growth. Clinical outcomes are already well-regarded, but reimbursement and guideline inclusion are key for broader adoption.
Q:Why is there renewed focus on the Sonalleve technology?
A:Interest in Sonalleve has increased due to the acquisition of HistoSonics for $2.25 billion, incoming calls from physicians, and promising results in treating uterine diseases and solid organ tumors. The technology's MRI-based approach is seen as a significant advantage.
Q:Review of Unclear Management Responses
A:Management avoided providing specific fallout rates for each stage of the pipeline, citing limited data due to the pipeline's newness. They also used vague language when discussing the timeline for closing deals and the impact of upcoming data reveals on growth.
You have reached the limit. Sign up to access full content
Get started
Earnings Word Cloud
The most frequently occurring keywords in this quarter's earning call
AI MRI
AI Volume
AI planning
AI treatment
AUA front
BPH procedure
Center
Chicago
Dr Profound
RSNA
Reduction software
Texas
Volume Reduction
basis
benefit
blood loss
capability
care
efficiency
financing plan
flexibility
hospital stay
incision
increase
lesion
need patient
outcome
partnership
path
pilot release
product launch
product release
release objective
session
shelf
success
surgeon
treatment design
volume reduction
PROF Transcript
Profound Medical Corp. (PRN:CA) Q1 2026 Earnings Call Transcript
Positive5-7
The earnings call presented strong financial performance with a 104% revenue increase YoY and improved gross margins. Despite a net loss, the reduction is notable. The Q&A highlighted a strong sales pipeline and positive reimbursement rates from private payers. While guidance was conservative, the company's bullish outlook and solid pipeline suggest potential growth. The market's response may be positive, especially with the anticipation of guideline recognition and commercial payer coverage. However, challenges in MR system integration and competitive pressures should be monitored. Overall, the sentiment leans towards a positive stock price movement.
Profound Medical Corp. (PRN:CA) Q3 2025 Earnings Call Transcript
Positive11-13
The earnings call reveals strong financial performance with an 87% revenue increase and improved gross margins. Positive guidance with 70%-75% growth expectations, supported by a robust pipeline, indicates optimism. The Q&A highlights significant commercial payer rates and Medicare reimbursement progress, enhancing profitability potential. While there are competitive and operational risks, the company's strategic focus on reimbursement and market access, along with promising clinical outcomes, supports a positive outlook. Despite some management vagueness, the overall sentiment is positive, likely resulting in a 2%-8% stock price increase.
Profound Medical Corp. (PROF) Q2 2025 Earnings Call Transcript
Positive8-14
The earnings call highlights strong financial performance with improved gross margins and revenue growth. The CAPTAIN trial data and positive feedback from physicians enhance confidence in TULSA's efficacy. Although there are increased operating expenses and net losses, management's optimistic guidance, strategic partnerships, and successful marketing initiatives signal potential for growth. The Q&A session confirms positive sentiment, with plans for reduced cash burn and strategic expansions. The absence of negative guidance, coupled with favorable reimbursement scenarios, supports a positive outlook for the stock price over the next two weeks.
Profound Medical Corporation (PROF) Q1 2025 Earnings Conference Call Transcript
Unknown5-9
The earnings call presents a mixed picture: strong revenue growth and promising product development (TULSA AI and CAPTAIN trial) are offset by increased net losses and operating expenses. The Q&A section reveals positive feedback on CAPTAIN data and insurer engagement, but management's vague responses on deal closures and financial guidance introduce uncertainty. The lack of shareholder return initiatives further tempers optimism. Despite potential for future growth, current financial instability and competitive pressures suggest a neutral stock price movement in the short term.
PROF Report
Frequently Asked Questions
Where does this earnings call transcript come from?
All transcripts are sourced directly from the official live webcast or the company’s official investor relations website. We use the exact words spoken during the call with no paraphrasing of the core discussion.
How soon is the transcript available after the earnings call ends?
Full verbatim transcripts are typically published within 4–12 hours after the call ends. Same-day availability is guaranteed for all S&P 500 and most mid-cap companies.
Is the transcript edited or altered in any way?
No material content is ever changed or summarized in the “Full Transcript” section. We only correct obvious spoken typos (e.g., “um”, “ah”, repeated 10 times”, or clear misspoken ticker symbols) and add speaker names/titles for readability. Every substantive sentence remains 100% as spoken.
Why do some answers appear as “Unclear” or “Inaudible”?
When audio quality is poor or multiple speakers talk over each other, we mark the section instead of guessing. This ensures complete accuracy rather than introducing potential errors.
Who creates the AI Summary and Key Q&A highlights shown above the transcript?
They are generated by a specialized financial-language model trained exclusively on 15+ years of earnings transcripts. The model extracts financial figures, guidance, and tone with 97%+ accuracy and is regularly validated against human analysts. The full raw transcript always remains available for verification.
